ASCLETIS-B (01672) rose more than 5% in early trading. At the time of writing, the stock was up 4.04%, trading at HK$15.45 with a turnover of HK$16.3476 million.

Information disclosed by the Hong Kong Stock Exchange shows that on May 7, the Singapore Government Investment Corporation (GIC) increased its holding in ASCLETIS-B by 122,000 ordinary shares, valued at approximately HK$2.0267 million. Following this purchase, GIC's total shareholding has risen to 74.808 million shares, representing a stake of 7%.

This increase in holding reflects GIC's continued confidence in ASCLETIS-B's innovative R&D capabilities, strategic execution, and long-term growth prospects. It also indicates sustained attention from international capital markets regarding the value of ASCLETIS-B's innovative pipeline.

It is noteworthy that the 13-week U.S. Phase II study of ASC30 for the treatment of type 2 diabetes has completed patient enrollment. Topline data from this Phase II study for type 2 diabetes is expected in the third quarter of 2026.

From an industry perspective, ASC30 has demonstrated superior weight loss data and a favorable safety profile. Furthermore, its molecular patent has been granted in the United States, suggesting significant business development potential.